Rituximab monotherapy is effective in patients with poor risk refractory aggressive non-Hodgkin's lymphoma.
We report the results of rituximab monotherapy in 21 patients with refractory or relapsed aggressive non Hodgkin s lymphoma (NHL). The majority of the patients (16/21) were refractory to conventional treatment and not eligible for high dose chemotherapy. Responses (1 complete and 6 partial) were achieved in some of these patients and their median overall survival was 8 months.
Rothe
Achim
A
Schulz
Holger
H
Elter
Thomas
T
Engert
Andreas
A
Reiser
Marcel
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab